Spots Global Cancer Trial Database for A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Official Title: A Phase 1 Study of JNJ-64407564, a Humanized GPRC5D * CD3 Bispecific Antibody in Japanese Subjects With Relapsed or Refractory Multiple Myeloma
Study ID: NCT04773522
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (MM) at the recommended Phase 2 dose (RP2D) identified in NCT03399799 study.
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Shonan Kamakura General Hospital, Kamakura-shi, , Japan
National Cancer Center Hospital East, Kashiwa, , Japan
Nagoya City University Hospital, Nagoya, , Japan
National Hospital Organization Okayama Medical Center, Okayama, , Japan
Japanese Red Cross Medical Center, Shibuya, , Japan
Iwate Medical University Hospital, Shiwa-gun, , Japan
Contact Details
Name: Janssen Pharmaceutical K.K., Japan Clinical Trial
Affiliation: Janssen Pharmaceutical K.K.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
